verstappen 追蹤 Lv.5 星期一 14:20 泰合 奧孟亞 瑩碩生技 展開 +3 2026為什麼是「GLP-1口服元年」？台灣公司怎麼受惠？ 繼續閱讀 2026 is the year of obesity pills. Here's how they could reshape the GLP-1 market Patients can already access the first GLP-1 obesity pill from Novo Nordisk, and a rival oral drug from Eli Lilly is slated for U.S. approval later this year. CNBC 13 2P 0則留言 打賞 分享 留言 讚 取消 送出 留言... 目前沒有任何討論
